MALVERN, Pa. — Endo Health Solutions on Tuesday announced that NuPathe has terminated its merger agreement. Endo received a $5 million termination fee from NuPathe.
"We believe that the agreement NuPathe has signed with Teva is positive news for NuPathe stockholders and as a result we accepted the termination fee and are now proceeding to withdraw our tender offer," Rajiv De Silva, president and CEO of Endo, said. "We believe our offer represented fair value for NuPathe. We will remain disciplined in our approach to M&A and will look to deploy capital on other opportunities to create value for our shareholders."